Shares of HUTCHMED (China) Limited (NASDAQ:HCM - Get Free Report) gapped down before the market opened on Tuesday . The stock had previously closed at $16.79, but opened at $16.01. HUTCHMED shares last traded at $15.95, with a volume of 1,309 shares.
Analyst Ratings Changes
HCM has been the subject of a number of research reports. Wall Street Zen lowered shares of HUTCHMED from a "strong-buy" rating to a "buy" rating in a research report on Saturday. HSBC downgraded shares of HUTCHMED from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th.
Read Our Latest Research Report on HCM
HUTCHMED Stock Performance
The business has a 50 day moving average of $14.45 and a 200-day moving average of $14.73. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.68 and a current ratio of 2.81.
Institutional Investors Weigh In On HUTCHMED
A number of institutional investors and hedge funds have recently modified their holdings of HCM. Barclays PLC lifted its stake in HUTCHMED by 1,483.6% in the 4th quarter. Barclays PLC now owns 2,407 shares of the company's stock worth $35,000 after purchasing an additional 2,255 shares in the last quarter. Public Employees Retirement System of Ohio increased its holdings in shares of HUTCHMED by 49.6% in the fourth quarter. Public Employees Retirement System of Ohio now owns 2,710 shares of the company's stock worth $39,000 after purchasing an additional 899 shares during the period. Summit Trail Advisors LLC raised its position in shares of HUTCHMED by 7.7% in the first quarter. Summit Trail Advisors LLC now owns 14,094 shares of the company's stock worth $212,000 after buying an additional 1,004 shares in the last quarter. OLD Mission Capital LLC bought a new stake in HUTCHMED during the fourth quarter valued at $230,000. Finally, Marshall Wace LLP purchased a new position in HUTCHMED during the fourth quarter worth about $261,000. 8.82% of the stock is owned by hedge funds and other institutional investors.
HUTCHMED Company Profile
(
Get Free Report)
HUTCHMED (China) Ltd. is a holding company, which engages in the research and development, manufacture, and sale of pharmaceuticals and health-oriented consumer products. It operates through the Oncology/Immunology and Other Ventures segments. The Oncology/Immunology segment includes the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider HUTCHMED, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and HUTCHMED wasn't on the list.
While HUTCHMED currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
